Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001193125-26-006350
Filing Date
2026-01-07
Accepted
2026-01-07 16:21:52
Documents
1
Period of Report
2026-01-05

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 3876
  Complete submission text file 0001193125-26-006350.txt   5347
Mailing Address 1000 N. WEST STREET, SUITE 1200 WILMINGTON DE 19801
Business Address 1000 N. WEST STREET, SUITE 1200 WILMINGTON DE 19801 (302) 295-3800
Inhibikase Therapeutics, Inc. (Issuer) CIK: 0001750149 (see all company filings)

EIN.: 263407249 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O ARENA PHARMACEUTICALS, INC. 6154 NANCY RIDGE DRIVE SAN DIEGO CA 92121
Business Address
Cabell Christopher (Reporting) CIK: 0001814928 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39676 | Film No.: 26515940